Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.

Cancer research - 15 May 2006

Yang Allen S, Doshi Ketan D, Choi Sang-Woon, Mason Joel B, Mannari Rajan K, Gharybian Vazganush, Luna Rene, Rashid Asif, Shen Lanlan, Estecio Marcos R H, Kantarjian Hagop M, Garcia-Manero Guillermo, Issa Jean-Pierre J

Abstract excerpt

5-Aza-2'-deoxycytidine (decitabine) is postulated to have clinical activity in myeloid leukemias via its ability to inhibit DNA methylation. To study this, we examined DNA methylation in patients with leukemia treated with decitabine. Five days after the treatment, total genomic 5-methylcytosine/cytosine decreased on average by 14% (from 4.3% to 3.7%), whereas methylation of repetitive DNA elements showed a mean...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Azacitidine

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Decitabine

Share to Genes, p53

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Leukemia, Myeloid, Acute

Share to RNA, Long Noncoding

Share to RNA, Untranslated

Source

Identifiers

PMID: 16707479
DOI: 10.1158/0008-5472.CAN-05-2385

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.PMID 16707479Read ↗

Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemiaSemantic proximity Read ↗

Epigenetic therapy of cancer with 5-aza-2'-deoxycytidine (decitabine).Semantic proximity Read ↗

Recurrent transcriptional responses in AML and MDS patients treated with decitabineSemantic proximity Read ↗

Evolution of decitabine developmentSemantic proximity Read ↗

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemiaSemantic proximity Read ↗

Decitabine and its role in the treatment of hematopoietic malignanciesSemantic proximity Read ↗

Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemiaSemantic proximity Read ↗

Genomic impact of transient low-dose decitabine treatment on primary AML cellsSemantic proximity Read ↗

Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatmentSemantic proximity Read ↗

Effects of 5-Aza-2′-deoxycytidine (decitabine) on gene expressionSemantic proximity Read ↗

Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.Semantic proximity Read ↗

Evaluation of a 7-Day Continuous Intravenous Infusion of Decitabine: Inhibition of Promoter-Specific and Global Genomic DNA MethylationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.